Integrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2023

Rhea-AI Summary

Integrated BioPharma reports financial results for Q2 and FY 2023. Revenue for Q2 2023 decreased by 2.3% compared to Q2 2022. Operating income for Q2 2023 was $79,000, a decrease from $438,000 in Q2 2022. Revenues for FY 2023 decreased by 9.8% compared to FY 2022. Operating income for FY 2023 was $120,000, a decrease from $2.7 million in FY 2022. Net income for Q2 2023 was $40,000, a decrease from $1.5 million in Q2 2022. Net loss for FY 2023 was $34,000, a decrease from net income of $3.8 million in FY 2022.

Positive

• None.

Negative

• Decreased revenue and operating income for both Q2 and FY 2023 compared to the same periods in 2022. Decreased net income and net loss for Q2 and FY 2023 compared to the same periods in 2022.

HILLSIDE, NJ / ACCESSWIRE / September 15, 2023 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter and fiscal year ended June 30, 2023.

Revenue for the quarter ended June 30, 2023 was $13.0 million compared to $13.3 million for the quarter ended June 30, 2022, a decrease of $0.3 million or 2.3%. The Company had operating income of approximately $79,000 and $438,000 in the quarters ended June 30, 2023 and 2022, respectively.

Revenues for the fiscal year ended June 30, 2023 were $50.7 million compared to $56.2 million for the fiscal year ended June 30, 2022, a decrease of $5.5 million or 9.8%. The Company had operating income for the fiscal year ended June 30, 2023 of approximately $120,000 compared to operating income of $2.7 million for the fiscal year ended June 30, 2022.

For the quarter ended June 30, 2023, the Company had net income of approximately $40,000 or $0.00 per share of common stock, compared with net income of $1.5 million or $0.05 per share of common stock for the quarter ended June 30, 2022. The Company's diluted net income per share of common stock for the quarters ended June 30, 2023 and 2022 were $0.00 and $0.05 per share of common stock, respectively.

For the fiscal year ended June 30, 2023, the Company had a net loss of approximately $34,000 or $0.00 per share of common stock, compared with net income of $3.8 million or $0.13 per share of common stock for the fiscal year ended June 30, 2022. The Company's diluted net income per share of common stock for the fiscal years ended June 30, 2023 and 2022 were $0.00 and $0.12 per share of common stock, respectively.

"While our revenue decreased by approximately 10% in the fiscal year ended June 30, 2023 from the prior fiscal year ended June 30, 2022 our revenue from our two largest customers in our Contract Manufacturing Segment remained consistent; representing approximately 89% and 90% of total revenue in the fiscal years ended June 30, 2023 and 2022, respectively," stated the Co-Chief Executive Officers of the Company, Riva Sheppard and Christina Kay. "Our Contract Manufacturing Segment contributed 95% of the total revenue in our fiscal year ended June 30, 2023 compared to 96% in the prior year, demonstrating growth in our other nutraceutical business segment, primarily in the warehousing and distribution business," the Co-CEO's further stated.

A summary of our financial results for the three months and fiscal years ended June 30, 2023 and 2022 follows:

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF INCOME (In thousands, except share and per share amounts) (unaudited)
	Three Months Ended						Fiscal Year Ended
	June 30,						June 30,
	2023			2022			2023			2022
Total revenue	$	12,994		$	13,267		$	50,672		$	56,246
Cost of sales		12,008			11,871			46,611			49,694
Gross profit		986			1,396			4,061			6,552
Selling and administrative expenses		907			958			3,941			3,807
Operating income		79			438			120			2,745
Other income (expense), net (1)		4		(31)			(20)			(148)
Income before income taxes		83			407			100			2,597
Income tax (expense) benefit, net	(43)				1,087		(134)				1,241
Net income (loss)	$	40		$	1,494		$ (34)			$	3,838
Net income (loss) per common share:
Basic	$	0.00		$	0.05		$	(0.00)		$	0.13
Diluted	$	0.00		$	0.05		$	(0.00)		$	0.12
Weighted average common shares outstanding:
Basic		29,949,610			29,886,614			29,949,610			29,843,387
Diluted		31,368,838			32,182,633			29,949,610			32,321,326
(1)Includes unrealized gain (loss) on investment in iBio, Inc. of $0, $(7), $28 and $(55), respectively, a non-cash item.

About Integrated BioPharma Inc. (INBP)

Integrated BioPharma, Inc. ("INBP") is engaged primarily in the business of manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. Further information is available at ir.ibiopharma.com.

This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, as well as assumptions, that, if they never materialize or prove incorrect, could cause the results of INBP to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements generally are identified by the words "expects," "anticipates," believes," intends," "estimates," "should," "would," "strategy," "plan" and similar expressions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements and are not guarantees of future performance. Such statements speak only as of the date hereof, are subject to change and should not be relied upon for investment purposes. INBP undertakes no obligation to revise or update any statements for any reasons. The risks, uncertainties and assumptions include, among others, changes in general economic and business conditions; loss of market share through competition; introduction of competing products by other companies; the timing of regulatory approval and the introduction of new products by INBP; changes in industry capacity; pressure on prices from competition or from purchasers of INBP's products; regulatory changes in the pharmaceutical manufacturing industry and nutraceutical industry; regulatory obstacles to the introduction of new technologies or products that are important to INBP; availability of qualified personnel; the loss of any significant customers or suppliers; the impact of the war in Ukraine; the tightened labor markets and inflation; and other risks and uncertainties described in the section entitled "Risk Factors" in INBP's most recent Annual Report on Form 10-K and its subsequent Quarterly Reports on Form 10-Q. Accordingly, INBP cannot give assurance that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of INBP.

Contact: Dina Masi, CFO
Integrated BioPharma, Inc.
investors@ibiopharma.com
888.319.6962

SOURCE: Integrated BioPharma, Inc.

View source version on accesswire.com:
https://www.accesswire.com/784667/integrated-biopharma-reports-results-for-its-quarter-and-fiscal-year-ended-june-30-2023